Clinical background of O2Vent
There are now many oral (mandibular advancement) devices on the market, as they have become an accepted form of treatment for people with sleep-disordered breathing. Recent research by Frost & Sullivan highlights and examines this growth of the oral appliance market in the United States.
The O2Vent is not only a mandibular advancement device but it also has an airway incorporated into it which directs the air flow from outside of the mouth through to the back of the throat. This is designed to bypass nasal and soft palate obstructions and prevent tongue obstructions.
The original design of the O2Vent (formerly the Oventus Clearway Device) has been used since 2009. At this time, a pilot study was conducted on the design with promising results. With further refinement and in particular using 3D printing technology, the device has been improved to be more user friendly with more airway capacity in a much more compact device.
Clinical success of oral devices in general
Studies show that more than 75 per cent of people with sleep-disordered breathing improve their sleep significantly using any oral device on the market.*
About 54 per cent improve to measure an AHI (Apnoea-Hypopnea Index) level of less than 10. Of those who do not improve to less than 10, 21 per cent of these will improve their AHI level by at least half.*
In fact, recent research has shown that using oral devices can be as effective as CPAP in the long term largely due to the increased compliance while using an oral appliance compared to CPAP.*
The severity of sleep apnoea based on the total number of complete cessations (apnoea) and partial obstructions (hypopnea) of breathing that occur per hour of sleep is measured using the Apnoea-Hypopnea Index (AHI). These pauses of breath must last for more than 10 seconds to be counted and measured by the decrease of oxygen in the blood.
* Kate Sutherland, et. al, Oral Appliance Treatment for Obstructive Sleep Apnea: An Update. Journal of Clinical Sleep Medicine. February 15 2014.